GYRO.NASDAQGyrodyne, LLC

S-1/A: Gyrodyne Seeks $5 Million Through Rights Offering to Bolster Liquidation Efforts

Sentiment:

Rights Offering Announcement


Gyrodyne, LLC is launching a rights offering to raise $5 million to support its liquidation strategy, including legal defenses and property entitlement pursuits.

Delay expectedThe process of negotiating purchase agreements, securing final subdivision approval and final unappealable site plan approval and consummating the sale of our properties will extend to year-end 2025.
Capital raiseGyrodyne is conducting a rights offering to raise up to $5 million.The offering grants shareholders the opportunity to purchase shares at $8.00 each, with one right issued for every five shares held as of January 29, 2024.The net proceeds, estimated at $4.4 million, will be used for legal defenses, property entitlement pursuits, and general working capital.
Worse than expectedThe company's liquidation timeline has been extended to year-end 2025, reducing net assets in liquidation by approximately $1.58 million.

Summary

  • Gyrodyne, LLC is offering non-transferable subscription rights to its shareholders to purchase up to 625,000 common shares at $8.00 per share.
  • The company aims to raise $5 million in gross proceeds from the rights offering, with an estimated $4.4 million net proceeds after expenses.
  • The funds will be used to strengthen the company's position during the liquidation process, including negotiating purchase agreements, defending property rights in ongoing legal proceedings (Article 78), and pursuing property entitlements.
  • Shareholders receive one subscription right for every five common shares owned as of January 29, 2024.
  • The rights offering includes a basic subscription privilege and an over-subscription privilege for additional shares if available.
  • Certain board members have indicated they intend to participate in the rights offering.
  • The company's strategy involves enhancing the value of its remaining properties for sale and ultimately dissolving after asset disposition and debt settlement.
  • Gyrodyne estimates net assets as of September 30, 2023, at $30.03 million, or $20.25 per common share.
  • The company believes the process of negotiating purchase agreements, securing final subdivision approval and final unappealable site plan approval and consummating the sale of our properties will extend to year-end 2025.
  • The company estimates that this extension of the timeline from year-end 2024 will result in a reduction of approximately $1.58 million in net assets in liquidation.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the rights offering provides a means to raise capital, it also highlights the challenges and delays in the company's liquidation process. The potential for dilution and the extended timeline contribute to a balanced outlook.

Positives

  • The rights offering allows existing shareholders to participate in the company's financing on a pro rata basis, minimizing dilution.
  • Certain directors have indicated their intention to participate in the offering, signaling confidence in the company's strategy.
  • The company has secured a term mortgage loan in the principal amount of $1,500,000 with LLYR Resources, LLC.
  • The shareholders approved the Stock Plan at the Annual Meeting.

Negatives

  • The rights offering may cause dilution for shareholders who do not participate.
  • The subscription price of $8.00 is below the recent market price of $9.98 on January 19, 2024, potentially leading to an immediate decrease in the trading price.
  • The company's liquidation timeline has been extended to year-end 2025, reducing net assets in liquidation by approximately $1.58 million.
  • The company is involved in an Article 78 proceeding, which could further delay the sale of its Flowerfield property.
  • The company estimates that the expenses of the rights offering will be approximately $600,000, irrespective of the number of shares we sell or the amount of proceeds we raise in the offering.

Risks

  • Failure to fully exercise subscription rights will result in dilution of ownership.
  • The market price of common shares could decline during or after the offering.
  • The company may cancel the rights offering at any time.
  • The company has broad discretion over the use of the net proceeds from the rights offering.
  • The company is subject to risks associated with proxy contests and other actions of activist shareholders.
  • The company's current real estate portfolio consists of two properties, and such concentration risk subjects us to an increased risk of significant loss if either property declines in value.
  • The company may not be able to settle all of our obligations to creditors at the amount we have estimated.
  • The company's shareholders may be liable to our creditors for an amount up to the amount distributed by us if our reserves for payments to creditors are inadequate.

Future Outlook

Gyrodyne intends to dissolve after it completes the disposition of its real property assets, applies the proceeds of such dispositions first to settle any debts and claims, pending or otherwise, against the Company, and then makes distributions to holders of Gyrodyne common shares.

Industry Context

Rights offerings are a common method for companies, particularly smaller ones, to raise capital by offering existing shareholders the opportunity to purchase additional shares, often at a discount. This approach can be more shareholder-friendly than other financing methods, but it also carries the risk of dilution if not fully subscribed.

Comparison to Industry Standards

  • Comparing Gyrodyne's situation to similar companies undergoing liquidation is challenging due to the unique nature of each company's assets and liabilities.
  • However, the rights offering structure is a fairly standard approach for companies seeking to raise capital from existing shareholders.
  • The subscription price discount is a key factor in determining the success of a rights offering, and the $8.00 price point, compared to the recent market price, will likely influence shareholder participation.
  • The company's ongoing legal challenges and the extended timeline for liquidation add complexity and uncertainty compared to more straightforward asset sales.

Legal Proceedings

  • The company is involved in an Article 78 proceeding challenging the granting of preliminary approval of the subdivision of its Flowerfield property.

Stakeholder Impact

  • Shareholders face potential dilution if they do not participate in the rights offering.
  • The company's employees are affected by the ongoing liquidation process and the company's ability to fund operations.
  • The company's creditors are impacted by the company's ability to settle its obligations.
  • The company's tenants are impacted by the company's ability to retain and attract tenants in our real estate portfolio.

Next Steps

  • Shareholders must decide whether to exercise their subscription rights before the expiration date.
  • The company will continue to pursue entitlements on its properties and defend its property rights in ongoing legal proceedings.
  • The company will seek to identify purchasers for its properties and execute purchase agreements.

Key Dates

DateDescription
March 2017Gyrodyne filed subdivision applications with respect to Cortlandt Manor and Flowerfield.
March 30, 2022Town of Smithtown Planning Board granted Gyrodyne's application for preliminary approval to divide the Flowerfield property.
April 26, 2022Incorporated Village of Head of the Harbor commenced an Article 78 Proceeding against the Town of Smithtown and Gyrodyne.
June 2022Gyrodyne and the Town of Smithtown filed motions to dismiss the Petition.
March 20, 2023Town of Cortlandt Town Board adopted the SEQRA findings statement and approved a Local Law establishing the Medical Oriented Zoning District (the MOD).
April 25, 2023Gyrodyne received a Nomination Notice from Star Equity Fund, LP.
August 11, 2023Star Equity submitted a shareholder proposal to the Company pursuant to Rule 14a-8 of the Securities Exchange Act of 1934.
September 5, 2023The Company entered into a Cooperation Agreement with Star Equity.
October 12, 2023The shareholders approved the Stock Plan at the Annual Meeting.
November 14, 2023Issuance of 91,628 restricted shares to certain directors in exchange for their respective benefits in the Retention Bonus Plan.
December 27, 2023The Company secured a term mortgage loan in the principal amount of $1,500,000 with LLYR Resources, LLC.
January 19, 2024Last reported sales price of our common shares on the Nasdaq Capital Market was $9.98 per share.
January 29, 2024Record date for the rights offering.
[]Commencement date of the rights offering.
[]Expiration date of the rights offering at 5:00 p.m., New York City time.
[]Anticipated delivery of shares purchased in this offering.

Keywords

rights offering, Gyrodyne, liquidation, common shares, subscription rights, property entitlements, Article 78 proceeding, real estate, Flowerfield, Cortlandt Manor

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.